1. Amyloid Beta (A4) Precursor Protein: A Potential Biomarker for Recurrent Nasopharyngeal Carcinoma
- Author
-
Zhong-Guo Liang, Kai-Guo Li, Xin-Bin Pan, Hui-Ling Meng, Xiao-Hui Yang, Ling Li, Fanyan Zeng, Xiao-Yu Li, Song Qu, and Xiao-Dong Zhu
- Subjects
0301 basic medicine ,Oncology ,medicine.medical_specialty ,Receiver operating characteristic ,biology ,Amyloid beta ,business.industry ,medicine.medical_treatment ,medicine.disease ,Tandem mass tag ,Radiation therapy ,03 medical and health sciences ,030104 developmental biology ,0302 clinical medicine ,Nasopharyngeal carcinoma ,030220 oncology & carcinogenesis ,Internal medicine ,Potential biomarkers ,medicine ,biology.protein ,Biomarker (medicine) ,Recurrent Nasopharyngeal Carcinoma ,business - Abstract
Background and aim Nasopharyngeal carcinoma (NPC) is one of the most common cancers in Southern China, Southeast Asia. Radiotherapy is the main treatment for NPC. Still, about 20% of patients with NPC have a recurrence. No effective serum biomarkers are available for recurrent nasopharyngeal carcinoma (rNPC) to date. This study aimed to explore whether amyloid beta (A4) precursor protein (APP) might serve as a valuable diagnostic and prognostic biomarker for patients with rNPC. Methods In a previous study, a tandem mass tag-based proteomic test was performed, which screened 59 differentially expressed proteins (DEPs) between nonrecurrent nasopharyngeal carcinoma (nrNPC) and rNPC. In this study, a protein-protein interaction was conducted to screen the key proteins among the 59 DEPs. APP was validated and evaluated by enzyme-linked immunosorbent assay in 70 serum samples [recurrence (n = 35) and no-recurrence (n = 35)]. Also, the receiver operating characteristic (ROC) curve was plotted to evaluate the predictive value of APP. Results The area under the ROC curve was 0.666 (95% CI: 0.514-0.818, P = 0.044). The best cutoff point of the relative expression levels for APP was 1.23 (concentration = 16.95 ng/mL), at which the sensitivity was 55.2% and the specificity was 90.9%. Conclusion The findings indicated that APP might be a valuable diagnostic and prognostic biomarker for patients with rNPC.
- Published
- 2019